Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

被引:0
|
作者
Mollazadegan, Kazhan [1 ]
Skogseid, Britt [1 ]
Botling, Johan [2 ]
Akerstrom, Tobias [3 ]
Eriksson, Barbro [1 ]
Welin, Staffan [1 ]
Sundin, Anders [3 ]
Crona, Joakim [1 ]
机构
[1] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[2] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[3] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden
关键词
pancreatic neuroendocrine tumor; highgrade; systemic therapy; treatment outcomes; ENETS CONSENSUS GUIDELINES; NEOPLASMS; CARCINOMA; G3; CHEMOTHERAPY;
D O I
10.1530/EC-21-0604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3 that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown. This was a single-center retrospective cohort study aimed to characterize treatment patterns and outcomes among patients with secondary panNET-G3. Radiological responses were assessed using the Response Evaluation Criteria in Solid Tumors version 1.1. A total of 22 patients were included and received a median of 2 (range, 1-4) treatment lines in 14 different combinations. Median overall survival (OS) was 9 months (interquartile range (IQR): 4.25-17.5). For the 15 patients who received platinum-etoposide chemotherapy, median OS was 7.5 months (IQR: 3.75-10) and median progression-free survival (PFS) was 4 months (IQR: 2.5-5.5). The 15 patients who received conventional panNET therapies achieved a median OS of 8 months (IQR: 5-16.75) and median PFS was 5.5 months (IQR: 2.75-8.25). We observed one partial response on Lu-177 DOTA-TATE therapy. In conclusion, this hypothesis-generating study failed to identify any promising treatment alternatives for patients with secondary panNET-G3. This demonstrates the need for both improved biological understanding of this particular NET entity and for designing prospective studies to further assess its treatment in larger patient cohorts.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Outcome of Systemic Therapy in Secondary High-Grade Pancreatic Neuroendocrine Tumors
    Mollazadegan, K.
    Botling, J.
    Welin, S.
    Eriksson, B.
    Skogseid, B.
    Sundin, A.
    Crona, J.
    NEUROENDOCRINOLOGY, 2020, 110 : 199 - 199
  • [2] High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors
    Botling, Johan
    Lamarca, Angela
    Bajic, Duska
    Norlen, Olov
    Lonngren, Vincent
    Kjaer, Josefine
    Eriksson, Barbro
    Welin, Staffan
    Hellman, Per
    Rindi, Guido
    Skogseid, Britt
    Crona, Joakim
    NEUROENDOCRINOLOGY, 2020, 110 (11-12) : 891 - 898
  • [3] Systemic Therapy for Pancreatic Neuroendocrine Tumors
    Wheless, Margaret
    Das, Satya
    CLINICAL COLORECTAL CANCER, 2022, 22 (01) : 34 - 44
  • [4] Systemic Therapy for Pancreatic Neuroendocrine Tumors
    Lavingia, Viraj
    Gohel, Shruti
    Sirohi, Bhawna
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (SUPPL 2) : 305 - 314
  • [5] The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation
    Backman, S.
    Botling, J.
    Nord, H.
    Ghosal, S.
    Stalberg, P.
    Juhlin, C. C.
    Hellman, P.
    Skogseid, B.
    Pacak, K.
    Mollazadegan, K.
    Akerstrom, T.
    Crona, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 20 - 20
  • [6] High-Grade, Stage 2 Mast Cell Tumors: Outcome in Dogs With Local and Systemic Therapy
    Burge, Rhonda
    Woolard, Kevin D.
    Willcox, Jennifer L.
    Rebhun, Robert B.
    Burton, Jenna H.
    Al-Nadaf, Sami
    Skorupski, Katherine A.
    JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 2023, 59 (04) : 167 - 176
  • [7] A real-life treatment cohort of pancreatic neuroendocrine tumors: High-grade increase in metastases confers poor survival
    Zhang, Wu-Hu
    Gao, He-Li
    Liu, Wen-Sheng
    Qin, Yi
    Ye, Zeng
    Lou, Xin
    Wang, Fei
    Zhang, Yue
    Chen, Xue-Min
    Chen, Jie
    Yu, Xian-Jun
    Zhuo, Qi-Feng
    Xu, Xiao-Wu
    Ji, Shun-Rong
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [8] Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors
    Kulke, Matthew H.
    SEMINARS IN ONCOLOGY, 2013, 40 (01) : 75 - 83
  • [9] Role of surgery in high-grade neuroendocrine tumors of the lung
    Bedirhan, Mehmet Ali
    Urer, Nur
    Seyrek, Yunus
    Arda, Naciye
    Fener, Neslihan
    Cansever, Levent
    Kiyik, Murat
    Altin, Sedat
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 30 (03): : 389 - 394
  • [10] Efficacy of Perioperative Chemotherapy for High-Grade Neuroendocrine Tumors
    Ogawa, H.
    Tanaka, Y.
    Kitamura, Y.
    Tanaka, H.
    Nishioka, Y.
    Tane, S.
    Nishio, W.
    Maniwa, Y.
    Yoshimura, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S574 - S575